Once Daily Versus Conventional Dosing of Asacol [mesalazine] in the Maintenance of Quiescent Ulcerative Colitis: A Randomized Pilot Trial

Trial Profile

Once Daily Versus Conventional Dosing of Asacol [mesalazine] in the Maintenance of Quiescent Ulcerative Colitis: A Randomized Pilot Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2013

At a glance

  • Drugs Mesalazine (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top